|NovaBay Pharmaceuticals, Inc.|
5980 Horton Street
United States - Map
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes topical non-antibiotic antimicrobial products for the eye care market. It operates through four segments: Dermatology, Ophthalmology, Urology, and Wound Care. The company focuses on addressing the unmet therapeutic needs of the topical anti-infective market. Its commercial products include the Neutrox family of products, including Avenova for the eye care market; Neutrophase for wound care; and CelleRx for the dermatology market. The companys products under development stage consist of Aganocide compounds, which are novel, synthetic anti-infectives designed to mimic the bodys defense against infection and developed to treat and prevent a range of local, non-systemic infections with a low likelihood of developing bacterial resistance. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds that cover various dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
|Mr. Mark M. Sieczkarek ,
Chairman, Interim Chief Exec. Officer, Interim Pres, Chairman of Compensation Committee and Member of Nominating and Corp. Governance Committee
|Mr. Thomas J. Paulson M.B.A.,
Chief Financial Officer, Treasurer and Sec.
|Mr. Roy J. Wu M.B.A.,
Sr. VP of Bus. and Corp. Devel.
|Dr. David W. Stroman Ph.D.,
Chair of The Ophthalmology Advisory Board and Sr. VP of Ophthalmic Product Devel.
|Mr. Glenn Moro ,
VP of Sales and Marketing for Avenova
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|